Gonal-f
(Follitropin alfa)Phase 3Small molecule
EMD SeronoFollitropin alfa is a fertility medication that helps stimulate the ovaries in women to produce eggs, and is also used to stimulate sperm production in men with certain fertility problems.[1] Gonal-f is currently being investigated across 5 indications[3], with its most advanced program in Phase 3.[1]
Gonal-f is one of 89 small molecule programs targeting Hypogonadism. It is currently in Phase 3.
5
Indications
29
Total Trials
2
Active Trials
88
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
121 competitors in Infertility
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskPhase 3
Voltaren
NovartisPhase 3
Zoladex
AstraZenecaPhase 3
Depo-Provera
Eli LillyPhase 3
Activella
Eli LillyPhase 3
Gonal-f
EMD SeronoPhase 3
Alli
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Prograf
VVeloxis Pharmaceuticals
Phase 3
Human Chorionic Gonadotropin
Merck & Co.Phase 3
Gas-X
PPortuguese Oncology Institute, Coimbra
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Controlled Ovarian Stimulation5 trials
Efficacy and Safety4 trials
Infertility3 trials
Pregnancy2 trials
9 more indications
Women2 trials
Intracytoplasmic Sperm Injection2 trials
Trial2 trials
Gene Expression1 trial
Frozen Embryo Transfer1 trial
Estradiol and Progesterone Levels Following Frozen Embryo Transfer
Completed·—·Phase 4·NCT04997525·305 enrolled
Observational Study1 trial
Regulatory
FDA Approval Timeline[4]
Sep 29, 1997
GONAL-F
BLA BLA020378
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Follitropin alfa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Follicle Stimulating Hormone Receptor Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company